Facial Nerve Paralysis and COVID-19 : A Systematic Review
© 2022 The American Laryngological, Rhinological and Otological Society, Inc..
OBJECTIVE: Several cases of facial nerve paralysis (FNP) post-COVID-19 infection have been reported with varying presentations and management. This study aims to identify FNP clinical characteristics and recovery outcomes among patients acutely infected with COVID-19. We hypothesize that FNP is a potentially unique sequalae associated with COVID-19 infections.
METHODS: A systematic review of PubMed-Medline, OVID Embase, and Web of Science databases from inception to November 2021 was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
RESULTS: This search identified 630 studies with 53 meeting inclusion criteria. This resulted in 72 patients, of which 30 (42%) were diagnosed with Guillain-Barré Syndrome (GBS). Non-GBS patients were on average younger (36 vs. 53 years) and more likely to present with unilateral FNP (88%) compared to GBS patients who presented predominantly with bilateral FNP (74%). Among non-GBS patients, majority (70%) of FNP presented a median of 8 [IQR 10] days after the onset of initial COVID-19 symptom(s). Treatment for non-GBS patients consisted of steroids (60%), antivirals (29%), antibiotics (21%), and no treatment (21%). Complete FNP recovery in non-GBS patients was achieved in 67% patients within a median of 11 [IQR 24] days.
CONCLUSION: FNP is a possible presentation post COVID-19 infections, associated with both GBS and non-GBS patients. Although no causation can be assumed, the clinical course of isolated FNP associated with COVID-19 raises the possibility of a unique presentation differing from Bell's palsy, seen with higher proportion of patients developing bilateral FNP and a shorter duration to complete recovery. Laryngoscope, 133:1007-1013, 2023.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:133 |
|---|---|
| Enthalten in: |
The Laryngoscope - 133(2023), 5 vom: 22. Mai, Seite 1007-1013 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Namavarian, Amirpouyan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bell's palsy |
|---|
| Anmerkungen: |
Date Completed 14.04.2023 Date Revised 23.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/lary.30333 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344581462 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344581462 | ||
| 003 | DE-627 | ||
| 005 | 20231226023112.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/lary.30333 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1148.xml |
| 035 | |a (DE-627)NLM344581462 | ||
| 035 | |a (NLM)35938708 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Namavarian, Amirpouyan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Facial Nerve Paralysis and COVID-19 |b A Systematic Review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.04.2023 | ||
| 500 | |a Date Revised 23.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The American Laryngological, Rhinological and Otological Society, Inc. | ||
| 520 | |a OBJECTIVE: Several cases of facial nerve paralysis (FNP) post-COVID-19 infection have been reported with varying presentations and management. This study aims to identify FNP clinical characteristics and recovery outcomes among patients acutely infected with COVID-19. We hypothesize that FNP is a potentially unique sequalae associated with COVID-19 infections | ||
| 520 | |a METHODS: A systematic review of PubMed-Medline, OVID Embase, and Web of Science databases from inception to November 2021 was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines | ||
| 520 | |a RESULTS: This search identified 630 studies with 53 meeting inclusion criteria. This resulted in 72 patients, of which 30 (42%) were diagnosed with Guillain-Barré Syndrome (GBS). Non-GBS patients were on average younger (36 vs. 53 years) and more likely to present with unilateral FNP (88%) compared to GBS patients who presented predominantly with bilateral FNP (74%). Among non-GBS patients, majority (70%) of FNP presented a median of 8 [IQR 10] days after the onset of initial COVID-19 symptom(s). Treatment for non-GBS patients consisted of steroids (60%), antivirals (29%), antibiotics (21%), and no treatment (21%). Complete FNP recovery in non-GBS patients was achieved in 67% patients within a median of 11 [IQR 24] days | ||
| 520 | |a CONCLUSION: FNP is a possible presentation post COVID-19 infections, associated with both GBS and non-GBS patients. Although no causation can be assumed, the clinical course of isolated FNP associated with COVID-19 raises the possibility of a unique presentation differing from Bell's palsy, seen with higher proportion of patients developing bilateral FNP and a shorter duration to complete recovery. Laryngoscope, 133:1007-1013, 2023 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Bell's palsy | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a facial nerve | |
| 650 | 4 | |a paralysis | |
| 650 | 7 | |a Steroids |2 NLM | |
| 700 | 1 | |a Eid, Anas |e verfasserin |4 aut | |
| 700 | 1 | |a Ziai, Hedyeh |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Emily YiQin |e verfasserin |4 aut | |
| 700 | 1 | |a Enepekides, Danny |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Laryngoscope |d 1945 |g 133(2023), 5 vom: 22. Mai, Seite 1007-1013 |w (DE-627)NLM000205370 |x 1531-4995 |7 nnns |
| 773 | 1 | 8 | |g volume:133 |g year:2023 |g number:5 |g day:22 |g month:05 |g pages:1007-1013 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/lary.30333 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 133 |j 2023 |e 5 |b 22 |c 05 |h 1007-1013 | ||